比较 ACE（血管紧张素转换酶）抑制剂和血管紧张素受体阻滞剂的一线疗效和安全性：一项多国队列研究。
Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.
机构信息
Department of Biomedical Informatics, Columbia University Irving Medical Center, New York (R.C., P.B.R., G.H.).
Department of Translational Data Science and Informatics, Geisinger, Danville, PA (R.C.).
出版信息
Hypertension. 2021 Sep;78(3):591-603. doi: 10.1161/HYPERTENSIONAHA.120.16667. Epub 2021 Jul 26.
Abstract
[Figure: see text].
摘要
[图：见正文]。
相似文献
1
Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.比较 ACE（血管紧张素转换酶）抑制剂和血管紧张素受体阻滞剂的一线疗效和安全性：一项多国队列研究。
Hypertension. 2021 Sep;78(3):591-603. doi: 10.1161/HYPERTENSIONAHA.120.16667. Epub 2021 Jul 26.
2
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.一线降压药类别全面比较效果和安全性：系统的、多国的、大规模分析。
Lancet. 2019 Nov 16;394(10211):1816-1826. doi: 10.1016/S0140-6736(19)32317-7. Epub 2019 Oct 24.
3
Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂的比较
Am Fam Physician. 2015 Feb 1;91(3):193-4.
4
Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.抗高血压药物与 COVID-19 风险：一项涉及 200 万高血压患者的队列研究。
Hypertension. 2021 Mar 3;77(3):833-842. doi: 10.1161/HYPERTENSIONAHA.120.16314. Epub 2021 Jan 11.
5
Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.治疗中难治性高血压（ResHypOT）：与肾素-血管紧张素-醛固酮系统双重阻断加比索洛尔相比，序贯肾单位阻断治疗难治性动脉高血压——一项随机对照试验的研究方案
Trials. 2018 Feb 12;19(1):101. doi: 10.1186/s13063-017-2343-3.
6
Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.血管紧张素转换酶（ACE）抑制剂与血管紧张素受体阻滞剂治疗原发性高血压的比较。
Cochrane Database Syst Rev. 2014 Aug 22;2014(8):CD009096. doi: 10.1002/14651858.CD009096.pub2.
7
Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.血管紧张素转换酶抑制剂比血管紧张素受体阻滞剂降低死亡率：系统评价和荟萃分析。
Eur J Prev Cardiol. 2017 Dec;24(18):1914-1924. doi: 10.1177/2047487317728766. Epub 2017 Sep 1.
8
Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.血管紧张素受体阻滞剂与癌症风险：在英国普通实践研究数据库中接受抗高血压药物治疗的人群中的队列研究。
BMJ. 2012 Apr 24;344:e2697. doi: 10.1136/bmj.e2697.
9
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?血管紧张素转换酶抑制剂在高血压中的应用：用还是不用？
J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482. doi: 10.1016/j.jacc.2018.01.058.
10
Choose ARBs Over ACE Inhibitors for First-line Hypertension Treatment, Large New Analysis Suggests.大型新分析表明，一线高血压治疗应选择ARB而非ACE抑制剂。
JAMA. 2021 Oct 5;326(13):1244-1245. doi: 10.1001/jama.2021.14017.
引用本文的文献
1
The Application of Mesoporous Silica Nanoparticles in Enhancing the Efficacy of Anti-Atherosclerosis Therapies: A Review.介孔二氧化硅纳米颗粒在增强抗动脉粥样硬化治疗效果中的应用：综述
Int J Nanomedicine. 2025 Aug 10;20:9825-9856. doi: 10.2147/IJN.S538100. eCollection 2025.
2
Angiotensin II and Atherosclerosis: A New Cardiovascular Risk Factor Beyond Hypertension.血管紧张素II与动脉粥样硬化：一种超越高血压的新型心血管危险因素。
Int J Mol Sci. 2025 Aug 4;26(15):7527. doi: 10.3390/ijms26157527.
3
CLEAR: A vision to support clinical evidence lifecycle with continuous learning.清晰：通过持续学习支持临床证据生命周期的愿景。
J Biomed Inform. 2025 Jul 29;169:104884. doi: 10.1016/j.jbi.2025.104884.
4
Comparative Risk Assessment in Hypertensive Patients With Metabolic Syndrome by Exploring Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers.通过探索血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂对高血压合并代谢综合征患者进行比较风险评估
Cureus. 2025 Jun 8;17(6):e85564. doi: 10.7759/cureus.85564. eCollection 2025 Jun.
5
Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction.G蛋白偶联受体的对接模拟揭示了多种配体与血管紧张素、α-肾上腺素能和阿片受体的交叉结合模式：对心血管疾病和成瘾的影响。
Biomolecules. 2025 Jun 11;15(6):855. doi: 10.3390/biom15060855.
6
Gating Mechanism for Biased Agonism at Angiotensin II Type 1 Receptors.血管紧张素II 1型受体偏向性激动的门控机制
Molecules. 2025 May 30;30(11):2399. doi: 10.3390/molecules30112399.
7
Exploring Ginseng Bioactive Compound's Role in Hypertension Remedy: An In Silico Approach.探索人参生物活性化合物在高血压治疗中的作用：一种计算机模拟方法。
Pharmaceuticals (Basel). 2025 Apr 28;18(5):648. doi: 10.3390/ph18050648.
8
Angiotensin-converting enzyme inhibitor-induced bowel angioedema: clinical features, diagnostic challenges, and recovery predictors from survival analysis: a systematic review of current reported cases.血管紧张素转换酶抑制剂所致肠道血管性水肿：临床特征、诊断挑战及生存分析中的恢复预测因素：对当前报告病例的系统评价
Ann Gastroenterol. 2025 May-Jun;38(3):276-283. doi: 10.20524/aog.2025.0967. Epub 2025 Apr 28.
9
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study.血管紧张素转换酶抑制剂与血管紧张素II受体阻滞剂对老年2型糖尿病患者心血管结局的比较疗效：一项目标试验模拟研究
Cardiovasc Diabetol. 2025 May 6;24(1):194. doi: 10.1186/s12933-025-02753-1.
10
High-Throughput Screening for Prescribing Cascades Among Real-World Angiotensin-II Receptor Blockers (ARBs) Initiators.对真实世界中血管紧张素II受体阻滞剂（ARB）起始治疗者的处方级联进行高通量筛选。
medRxiv. 2025 Mar 11:2025.03.10.25323711. doi: 10.1101/2025.03.10.25323711.
本文引用的文献
1
Treatment Patterns for Chronic Comorbid Conditions in Patients With Cancer Using a Large-Scale Observational Data Network.利用大规模观察性数据网络对癌症患者慢性合并症的治疗模式
JCO Clin Cancer Inform. 2020 Mar;4:171-183. doi: 10.1200/CCI.19.00107.
2
Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension.比较氯噻酮与氢氯噻嗪治疗高血压的心血管和安全性结局。
JAMA Intern Med. 2020 Apr 1;180(4):542-551. doi: 10.1001/jamainternmed.2019.7454.
3
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.一线降压药类别全面比较效果和安全性：系统的、多国的、大规模分析。
Lancet. 2019 Nov 16;394(10211):1816-1826. doi: 10.1016/S0140-6736(19)32317-7. Epub 2019 Oct 24.
4
2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension.2018年韩国高血压学会高血压管理指南：第二部分——高血压的诊断与治疗
Clin Hypertens. 2019 Aug 1;25:20. doi: 10.1186/s40885-019-0124-x. eCollection 2019.
5
Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.血红蛋白 A1c 水平与二甲双胍治疗的 2 型糖尿病患者使用磺酰脲类、二肽基肽酶 4 抑制剂和噻唑烷二酮类药物的相关性：来自观察性健康数据科学和信息学倡议的分析。
JAMA Netw Open. 2018 Aug 3;1(4):e181755. doi: 10.1001/jamanetworkopen.2018.1755.
6
2018 ESC/ESH Guidelines for the management of arterial hypertension.2018年欧洲心脏病学会/欧洲高血压学会动脉高血压管理指南。
Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339.
7
Improving reproducibility by using high-throughput observational studies with empirical calibration.通过使用经实证校准的高通量观察性研究提高可重复性。
Philos Trans A Math Phys Eng Sci. 2018 Sep 13;376(2128). doi: 10.1098/rsta.2017.0356.
8
Evaluating large-scale propensity score performance through real-world and synthetic data experiments.通过真实数据和合成数据实验评估大规模倾向评分性能。
Int J Epidemiol. 2018 Dec 1;47(6):2005-2014. doi: 10.1093/ije/dyy120.
9
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?血管紧张素转换酶抑制剂在高血压中的应用：用还是不用？
J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482. doi: 10.1016/j.jacc.2018.01.058.
10
Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data.基于观察性医疗保健数据的人群效应估计研究的经验置信区间校准。
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):2571-2577. doi: 10.1073/pnas.1708282114.
Zotero 插件